Evolva pays €550,000 for Fluxome resveratrol business

Swiss biotech firm Evolva has bought failing Fluxome's, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.

URL: http://www.nutraingredients-usa.com/Industry/Evolva-pays-550-000-for-Fluxome-resveratrol-business?utm_source=RSS_text_news&utm_medium=RSS%2Bfeed&utm_campaign=RSS%2BText%2BNews
Enclosure: http://www.nutraingredients-usa.com/var/plain_site/storage/images/publications/food-beverage-nutrition/nutraingredients.com/industry/evolva-pays-550-000-for-fluxome-resveratrol-business/7738984-1-eng-GB/Evolva-pays-550-000-for-Fluxome-resveratrol-business_rss.jpg